All In Biotech

BLA 761170 · Genentech INC

Phesgo

Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf · Subcutaneous · Endoglycosidase; HER2/neu Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 29, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

382

92 Phase 3, 90 recruiting

FAERS reports

4,830

1,826 serious, 292 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: PHESGO administration can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue PHESGO for cardiomyopathy. ( 2.3 , 5.1 ) Embryo-fetal Toxicity: Exposure to PHESGO can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception. ( 5.2 , 8.1 , 8.3 ) Pulmonary Toxicity: Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.3 ) Cardiomyopathy PHESGO administration can result in...

What it is approved for

From the label in effect Sep 23, 2026.

PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy...

Mechanism: Pertuzumab targets the extracellular dimerization domain (subdomain II) of HER2 and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signaling pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. Trastuzumab binds to subdomain IV of the extracellular domain of the HER2 protein to inhibit the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PHESGO · PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF 1,200MG · INJECTABLE, SUBCUTANEOUS · Prescription
  • PHESGO · PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF 600MG · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pertuzumab" as an intervention, any sponsor and status, largest first.

All 382 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event912
  • off label use902
  • diarrhoea432
  • injection site pain213
  • pain212
  • death164
  • fatigue163
  • injection site reaction162
  • pyrexia157
  • disease progression142
  • rash140
  • asthenia137

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20205
202151
2022195
2023388
20242,853
2025763
2026575

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Phesgo (Pertuzumab-Trastuzumab-Hy-Zzxf)

2024 spending

$2.4M

Beneficiaries

39

277 claims

Per beneficiary

$62,563

$855.98 per unit

View as table
YearSpending
2020$0
2021$317,403
2022$1,128,598
2023$1,262,939
2024$2,439,952

Part B: Phesgo (Pertuzumab-Trastuzumab-Hy-Zzxf) · HCPCS J9316

2024 spending

$125M

Beneficiaries

2,301

15,768 claims

Per beneficiary

$54,234

2024 ASP limit $65.82 per unit

View as table
YearSpending
2020$0
2021$25,073,292
2022$58,778,025
2023$92,589,276
2024$124,792,586

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 371 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.